These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35685644)

  • 1. Editorial: Pharmacoepidemiology in Diabetes Mellitus and its Complications: Focus on Response to Medications.
    Mohammadi Jouabadi S; Ahluwalia TS; Muka T; Ahmadizar F
    Front Pharmacol; 2022; 13():917977. PubMed ID: 35685644
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs.
    Lapeyre-Mestre M; Montastruc F
    Therapie; 2019 Apr; 74(2):209-214. PubMed ID: 30792079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.
    Dostalek M; Akhlaghi F; Puzanovova M
    Clin Pharmacokinet; 2012 Aug; 51(8):481-99. PubMed ID: 22668340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.
    Singh S
    Curr Diab Rep; 2014 Dec; 14(12):563. PubMed ID: 25363547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.
    Preston RA; Chung M; Gaffney M; Alonso A; Baltodano NM; Epstein M
    J Clin Pharmacol; 2001 Nov; 41(11):1215-24. PubMed ID: 11697754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
    Clements JN; Threatt T; Ward E; Shealy KM
    Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus.
    Jaber LA; Ducharme MP; Halapy H
    Ther Drug Monit; 1996 Feb; 18(1):6-13. PubMed ID: 8848822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.
    Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
    J Clin Psychiatry; 2006 Jul; 67(7):1055-61. PubMed ID: 16889448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus.
    Poggi JC; Barissa GR; Donadi EA; Foss MC; Cunha FQ; Lanchote VL; dos Reis ML
    J Clin Pharmacol; 2006 Nov; 46(11):1328-36. PubMed ID: 17050798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
    Bergman A; Tan B; Somayaji VR; Calle RA; Kazierad DJ
    Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.
    Gwilt PR; Nahhas RR; Tracewell WG
    Clin Pharmacokinet; 1991 Jun; 20(6):477-90. PubMed ID: 2044331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.
    Salvo F; Faillie JL
    Therapie; 2019 Apr; 74(2):255-260. PubMed ID: 30470475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus.
    Leal N; Calvo R; Agrad FZ; Lukas JC; de la Fuente L; Suarez E
    J Pharm Pharmacol; 2005 Mar; 57(3):317-25. PubMed ID: 15807987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.